Decoy TRAIL receptor CD264: a cell surface marker of cellular aging for human bone marrow-derived mesenchymal stem cells
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Mesenchymal stem cells (MSCs) are a mixture of progenitors that are heterogeneous in their regenerative potential. Development of MSC therapies with consistent efficacy is hindered by the absence of an immunophenotype of MSC heterogeneity. This study evaluates decoy TRAIL receptor CD264 as potentially the first surface marker to detect cellular aging in heterogeneous MSC cultures. CD264 surface expression, regenerative potential, and metrics of cellular aging were assessed in vitro for marrow MSCs from 12 donors ages 20–60 years old. Male and female donors were age matched. Expression of CD264 was compared with that of p16, p21, and p53 during serial passage of MSCs. When CD264 + cell content was 20% to 35%, MSC cultures from young (ages 20–40 years) and older (ages 45–60 years) donors proliferated rapidly and differentiated extensively. Older donor MSCs containing < 35% CD264 + cells had a small size and negligible senescence despite the donor’s advanced chronological age. Above the 35% threshold, CD264 expression inversely correlated with proliferation and differentiation potential. When CD264 + cell content was 75%, MSCs were enlarged and mostly senescent with severely compromised regenerative potential. There was no correlation of the older donors’ chronological age to either CD264 + cell content or the regenerative potential of the donor MSCs. CD264 was upregulated after p53 and had a similar expression profile to that of p21 during serial passage of MSCs. No sex-linked differences were detected in this study. These results suggest that CD264 is a surface marker of cellular age for MSCs, not the chronological age of the MSC donor. CD264 is first upregulated in MSCs at an intermediate stage of cellular aging and remains upregulated as aging progresses towards senescence. The strong inverse correlation of CD264 + cell content to the regenerative potential of MSCs has possible application to assess the therapeutic potential of patient MSCs, standardize the composition and efficacy of MSC therapies, and facilitate aging research on MSCs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adult mesenchymal stem cells for tissue engineering versus regenerative medicine
Caplan, A. I. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.21200 · Cited by 1,956 · cited 1×
“Background The remarkable regenerative capacity and numerous therapeutic applications of mesenchymal stem cells (MSCs) are well documented [1, 2]; however, the underlying cellular heterogeneity of MSCs remains a major impediment to the standardization and optimization of MSC therapies for clinical use.”
Debacq-Chainiaux, F., Erusalimsky, J. D., Campisi, J., & Toussaint, O. (2009) · Nature Protocols · doi:10.1038/nprot.2009.191 · Cited by 1,668
Senescence in premalignant tumours
Collado, M., Gil, J., Efeyan, A., Guerra, C., Schuhmacher, A. J., Barradas, M., Benguría, A., Zaballos, A., Flores, J. M., Barbacid, M., et al. (2005) · Nature · doi:10.1038/436642a · Cited by 1,482 · cited 4×
“A link of CD264 to senescence was first reported for oncogene-induced senescence; CD264 was upregulated in senescent premalignant tumors induced by ras but was downregulated in the ras-induced tumors that had escaped senescence and became malignant [23].”
InfluentialReversal of human cellular senescence: roles of the p53 and p16 pathways
Beauséjour, C. M., Krtolica, A., Galimi, F., Narita, M., Lowe, S. W., Yaswen, P., & Campisi, J. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg417 · Cited by 1,457
Alcorta, D. A., Xiong, Y., Phelps, D., Hannon, G., Beach, D., & Barrett, J. C. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.13742 · Cited by 1,008 · cited 1×
“Upregulation of p16 is a key event in the terminal phase of cell cycle arrest and senescence [55].”
Stem cells, ageing and the quest for immortality
Rando, T. A. (2006) · Nature · doi:10.1038/nature04958 · Cited by 695 · cited 1×
“Differences between the chronological age of an organism and cellular age of its tissues can arise in high-turnover tissues when cells replicate regularly, leading to an accumulation of DNA damage [46].”
Rejuvenation of the muscle stem cell population restores strength to injured aged muscles
Cosgrove, B. D., Gilbert, P. M., Porpiglia, E., Mourkioti, F., Lee, S. P., Corbel, S. Y., Llewellyn, M. E., Delp, S. L., & Blau, H. M. (2014) · Nature Medicine · doi:10.1038/nm.3464 · Cited by 677 · cited 2×
“Existing rejuvenation strategies have used, for instance, transient p38 inhibition to improve the regenerative capacity of aging skeletal muscle stem cells [18].”
The p53 network: cellular and systemic DNA damage responses in aging and Cancer
Reinhardt, H. C., & Schumacher, B. (2012) · Trends in Genetics · doi:10.1016/j.tig.2011.12.002 · Cited by 458
Rapamycin decelerates cellular senescence
Demidenko, Z. N., Zubova, S. G., Bukreeva, E. I., Pospelov, V. A., Pospelova, T. V., & Blagosklonny, M. V. (2009) · Cell Cycle · doi:10.4161/cc.8.12.8606 · Cited by 391 · cited 1×
“Similarly, rapamycin restored growth of fibrosarcoma cells 3 days after the onset of senescence, but it had only a minimal improvement after the cells were senescent for 9 days [60].”
The Origins of Mesenchymal Stromal Cell Heterogeneity
Pevsner-Fischer, M., Levin, S., & Zipori, D. (2011) · Stem Cell Reviews and Reports · doi:10.1007/s12015-011-9229-7 · Cited by 251 · cited 2×
“Cell-to-cell variation in the regenerative properties of MSCs has been attributed to distinct in vivo phenotypes, ex vivo culturing conditions, and cell senescence [7, 8].”
Cited by
A guide to assessing cellular senescence in vitro and in vivo
González‐Gualda, E., Baker, A. G., Fruk, L., & Muñoz‐Espín, D. (2021) · The FEBS Journal · doi:10.1111/febs.15570 · Cited by 645
Liu, J., Ding, Y., Liu, Z., & Liang, X. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00258 · Cited by 270
Regulation of Survival Networks in Senescent Cells: From Mechanisms to Interventions
Soto-Gamez, A., Quax, W. J., & Demaria, M. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.05.036 · Cited by 175
The Emergence of Senescent Surface Biomarkers as Senotherapeutic Targets
Rossi, M., & Abdelmohsen, K. (2021) · Cells · doi:10.3390/cells10071740 · Cited by 71
Metadata
- Authors
- Madsen, S. D., Russell, K. C., Tucker, H. A., Glowacki, J., Bunnell, B. A., & O’Connor, K. C.
- Venue
- Stem Cell Research & Therapy
- Published
- 2017-09-29
- Volume
- 8
- Issue
- 1
- Pages
- 201-201
- ISSN
- 1757-6512 (ISSN-L)
- OpenAlex
- W2758799065
- Cited by
- 50
- References
- 11
- FWCI
- 1.74
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Decoy TRAIL receptor CD264: a cell surface marker of cellular aging for human bone marrow-derived mesenchymal stem cells. https://app.cochat.ai/papers/10.1186/s13287-017-0649-4
- The paper
- Madsen, S. D., Russell, K. C., Tucker, H. A., Glowacki, J., Bunnell, B. A., & O’Connor, K. C. (2017). Decoy TRAIL receptor CD264: a cell surface marker of cellular aging for human bone marrow-derived mesenchymal stem cells. Stem Cell Research & Therapy. https://doi.org/10.1186/s13287-017-0649-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.